Clinical trial of BLX-7006
Latest Information Update: 16 Sep 2024
At a glance
- Drugs MLX 7000 (Primary)
- Indications Obesity; Type 2 diabetes mellitus; Weight loss
- Focus Adverse reactions
- Sponsors Biolexis Therapeutics
- 16 Sep 2024 New trial record
- 12 Sep 2024 According to a Biolexis Therapeutics media release, company showing intent for human clinical trials scheduled for early 2025.